1. A 58-year-old man with heterozygous familial hypercholesterolemia (FH) is on high-intensity rosuvastatin 40 mg daily. His LDL-C has decreased from 290 mg/dL to 178 mg/dL — a 39% reduction — which falls short of his treatment target. His physician explains that the statin itself has partially undermined its own LDL-lowering effect through a counter-regulatory mechanism, and that adding a PCSK9 inhibitor will amplify receptor-mediated LDL clearance beyond what the statin alone can achieve. Which of the following best describes the mechanism by which statin therapy paradoxically limits its own maximal LDL-C-lowering effect?
A) Statin-induced upregulation of ATP-binding cassette transporter G5/G8 (ABCG5/G8) increases biliary cholesterol excretion, reducing the enterohepatic cholesterol pool and thereby blunting compensatory LDL receptor (LDLR) upregulation.
B) Statin-induced intracellular cholesterol depletion upregulates PCSK9 expression via the sterol regulatory element-binding protein 2 (SREBP-2) pathway, increasing LDLR degradation and partially offsetting the statin-induced increase in LDLR surface density.
C) Statin therapy suppresses apolipoprotein B-100 (apoB-100) synthesis in the liver, reducing VLDL secretion and consequently decreasing LDL production — an effect that plateaus at high statin doses due to transcriptional feedback from residual intrahepatic cholesterol.
D) Statin-mediated inhibition of HMG-CoA reductase reduces synthesis of geranylgeranyl pyrophosphate, which normally stabilizes LDLR mRNA, so receptor upregulation is self-limiting once isoprenoid intermediates fall below a threshold level.
E) Statins reduce hepatic cholesterol synthesis sufficiently to activate liver X receptor (LXR) signaling, which induces IDOL (inducible degrader of the LDLR), an E3 ubiquitin ligase that targets LDLR for proteasomal degradation independently of PCSK9.
ANSWER: B
Rationale:
The correct answer is B. Statins inhibit HMG-CoA reductase, depleting intrahepatic cholesterol and activating the SREBP-2 transcription factor. SREBP-2 simultaneously upregulates LDLR expression — the desired pharmacological effect — and upregulates PCSK9, a serine protease that binds LDLR on the hepatocyte surface and routes it to lysosomal degradation rather than recycling. This PCSK9 co-induction is the primary counter-regulatory mechanism that limits statin monotherapy efficacy: as LDLR surface density rises, so does PCSK9-mediated receptor destruction, creating a ceiling on receptor-mediated LDL clearance. This mechanistic insight directly explains the synergy of statin plus PCSK9 inhibitor combination therapy — the statin drives SREBP-2-mediated LDLR upregulation while the PCSK9 inhibitor prevents the co-induced PCSK9 from negating that upregulation, resulting in far greater receptor surface density than either agent achieves alone.
Option A: Option A is incorrect; ABCG5/G8 transports plant sterols and cholesterol into bile, and statin-induced upregulation of this transporter does not blunt LDLR upregulation — it is not a counter-regulatory mechanism relevant to statin ceiling effects.
Option C: Option C is incorrect; statins do not meaningfully suppress apoB-100 synthesis or VLDL secretion as a primary mechanism, and VLDL reduction is not the basis for their LDL-C-lowering effect.
Option D: Option D is incorrect; geranylgeranyl pyrophosphate is a mevalonate pathway intermediate involved in protein prenylation and implicated in some statin pleiotropic effects, but it does not stabilize LDLR mRNA — LDLR is transcriptionally regulated by SREBP-2, not by isoprenoid intermediates.
Option E: Option E is incorrect; statins reduce, not increase, intrahepatic cholesterol, making LXR activation (which requires oxysterol ligands derived from cholesterol excess) implausible; while IDOL is a real E3 ligase that targets LDLR, it is induced by LXR under cholesterol-replete conditions, the opposite of the statin context.
2. A 63-year-old woman with established atherosclerotic cardiovascular disease (ASCVD) has been on high-intensity atorvastatin 80 mg daily for two years. Her LDL-C is 82 mg/dL, which remains above her treatment target of less than 70 mg/dL. Her physician adds ezetimibe 10 mg daily and explains that the combination will produce LDL-C lowering that is additive to — and mechanistically distinct from — the statin. Four weeks later her LDL-C is 61 mg/dL. Which of the following best explains why ezetimibe produces additional LDL-C lowering that is complementary rather than redundant to statin therapy?
A) Ezetimibe inhibits hepatic HMG-CoA reductase by a mechanism distinct from statins, reducing de novo cholesterol synthesis in a pathway not subject to the same SREBP-2-mediated feedback upregulation that limits statin monotherapy.
B) Ezetimibe activates peroxisome proliferator-activated receptor alpha (PPAR-α) in the liver, which suppresses apolipoprotein C-III (apoC-III) synthesis and secondarily reduces VLDL secretion, lowering the substrate available for LDL production.
C) Ezetimibe inhibits farnesyl pyrophosphate synthase in the mevalonate pathway, reducing cholesterol synthesis in enterocytes while leaving hepatic synthesis intact, creating an organ-selective cholesterol depletion that upregulates only intestinal cholesterol transporters.
D) Ezetimibe inhibits Niemann-Pick C1-Like 1 protein (NPC1L1) in intestinal enterocytes, reducing cholesterol absorption and decreasing cholesterol delivery to the liver; hepatic cholesterol depletion then triggers SREBP-2-mediated LDLR upregulation, producing additive LDL clearance by a pathway independent of HMG-CoA reductase inhibition.
E) Ezetimibe prevents re-esterification of free cholesterol in enterocytes by inhibiting acyl-CoA:cholesterol acyltransferase 2 (ACAT2), trapping absorbed cholesterol in the free form and rendering it unavailable for chylomicron packaging and delivery to the liver.
ANSWER: D
Rationale:
The correct answer is D. Ezetimibe selectively inhibits NPC1L1 (Niemann-Pick C1-Like 1 protein), a sterol transporter located on the apical brush border of intestinal enterocytes and on hepatocyte canalicular membranes. Inhibition of NPC1L1 reduces the absorption of both dietary and biliary cholesterol from the gut lumen into enterocytes, decreasing cholesterol delivery to the liver via chylomicron remnants. The resulting reduction in hepatic cholesterol content activates SREBP-2, which upregulates LDLR expression — the same transcriptional pathway that statins activate, but triggered by reduced cholesterol input rather than reduced synthesis. This is why the combination is additive: statins reduce hepatic cholesterol synthesis, while ezetimibe reduces cholesterol absorption, and both mechanisms converge on SREBP-2-mediated LDLR upregulation. The statin plus ezetimibe combination typically achieves approximately 60 to 65 percent LDL-C reduction from untreated baseline, compared to approximately 50 percent for high-intensity statin alone.
Option A: Option A is incorrect; ezetimibe does not inhibit HMG-CoA reductase by any mechanism — it has no activity at this enzyme.
Option B: Option B is incorrect; ezetimibe does not activate PPAR-α and has no meaningful effect on apoC-III synthesis or VLDL secretion — that mechanism describes the fibrate class.
Option C: Option C is incorrect; ezetimibe has no activity at farnesyl pyrophosphate synthase, which is the target of bisphosphonates in bone metabolism; ezetimibe acts exclusively at NPC1L1.
Option E: Option E is incorrect; ezetimibe does not inhibit ACAT2. ACAT2 inhibition was studied as a lipid-lowering strategy in separate drug development programs (e.g., pactimibe) but proved ineffective and is not the mechanism of ezetimibe.
3. A 55-year-old man with type 2 diabetes mellitus, metabolic syndrome, and fasting triglycerides of 520 mg/dL presents for cardiovascular risk assessment. A standard lipid panel calculated by the Friedewald equation returns an LDL-C of 64 mg/dL. His physician is uncertain whether this value accurately reflects his atherogenic LDL burden and orders a directly measured LDL-C, which returns at 91 mg/dL. Which of the following best explains why the Friedewald-calculated LDL-C is systematically inaccurate in patients with severe hypertriglyceridemia?
A) The Friedewald equation estimates LDL-C as total cholesterol minus HDL-C minus (triglycerides divided by 5); the divisor of 5 assumes a fixed ratio of triglycerides to VLDL cholesterol that holds only when triglycerides are below approximately 400 mg/dL, and severe hypertriglyceridemia inflates VLDL-C far beyond this fixed estimate, causing systematic underestimation of LDL-C.
B) The Friedewald equation overestimates HDL-C in hypertriglyceridemic states because triglyceride-enriched HDL particles are denser than normal HDL and co-precipitate with LDL during the ultracentrifugation step used to calibrate the assay, artificially elevating the HDL-C term and thereby reducing the calculated LDL-C.
C) The Friedewald equation underestimates total cholesterol in patients with severe hypertriglyceridemia because the enzymatic cholesterol assay is competitively inhibited by excess triglycerides, producing a falsely low starting value from which LDL-C is derived.
D) Severe hypertriglyceridemia causes LDL particles to acquire additional triglycerides via cholesteryl ester transfer protein (CETP)-mediated lipid exchange, converting them to triglyceride-enriched, cholesterol-depleted small dense LDL particles that carry less cholesterol per particle, causing the Friedewald equation to overestimate rather than underestimate LDL-C.
E) The Friedewald equation relies on a constant apolipoprotein B-100 (apoB-100) correction factor that becomes unreliable when VLDL particles are triglyceride-enriched, because larger VLDL particles carry proportionally more apoB-100 per unit triglyceride than the equation assumes, leading to double-counting of VLDL-associated cholesterol.
ANSWER: A
Rationale:
The correct answer is A. The Friedewald equation calculates LDL-C as: LDL-C = Total Cholesterol − HDL-C − (TG ÷ 5). The term TG ÷ 5 estimates VLDL cholesterol (VLDL-C) based on the empirical observation that the ratio of triglycerides to cholesterol in VLDL particles is approximately 5:1 under fasting conditions in normotriglyceridemic individuals. When triglycerides are markedly elevated — as in this patient with a fasting TG of 520 mg/dL — VLDL particles are abnormally triglyceride-enriched, and the 5:1 ratio no longer holds: actual VLDL-C is substantially higher than TG ÷ 5 predicts. Because VLDL-C is underestimated, the residual value attributed to LDL-C is also underestimated, producing a falsely low calculated LDL-C. The Martin-Hopkins equation, which uses a variable TG-to-VLDL-C ratio stratified by non-HDL-C and TG levels, improves accuracy in hypertriglyceridemia, as does direct LDL-C measurement by preparative ultracentrifugation or beta-quantification. For clinical decision-making in patients with TG above 400 mg/dL, direct measurement or non-HDL-C should replace Friedewald-calculated LDL-C.
Option B: Option B is incorrect; HDL-C is not measured by ultracentrifugation in standard clinical assays — it is measured after precipitation of apoB-containing lipoproteins or by direct homogeneous assays; triglycerides do not cause HDL-C overestimation through the described mechanism.
Option C: Option C is incorrect; the enzymatic cholesterol assay is not competitively inhibited by excess triglycerides under standard laboratory conditions; total cholesterol measurement is reliable across the triglyceride range encountered clinically.
Option D: Option D is incorrect in its characterization of the Friedewald error direction; while CETP-mediated triglyceride enrichment of LDL does produce small dense LDL particles with less cholesterol per particle, this is a real phenomenon but is not the mechanism by which the Friedewald equation errs — the equation's error is in VLDL-C estimation, not in LDL particle cholesterol content.
Option E: Option E is incorrect; the Friedewald equation contains no apoB-100 correction factor whatsoever — it is a purely cholesterol-mass-based equation.
4. A 47-year-old woman presents for routine evaluation. Her fasting lipid panel shows LDL-C 196 mg/dL, total cholesterol 264 mg/dL, and HDL-C 52 mg/dL. She has no secondary causes identified at initial review and no personal or family history of premature cardiovascular disease. Before initiating high-intensity statin therapy, her physician orders one additional laboratory test that returns as follows: thyroid-stimulating hormone (TSH) 18.4 mIU/L (reference 0.4–4.0 mIU/L). The patient is diagnosed with overt hypothyroidism. Which of the following best explains the mechanism by which hypothyroidism produces elevated LDL-C?
A) Thyroid hormone deficiency reduces hepatic triglyceride lipase (HL) activity, impairing IDL-to-LDL conversion and causing IDL accumulation; the resulting lipoprotein particles co-migrate with LDL in the standard density fractionation used by clinical lipid panels, producing apparent LDL-C elevation that resolves when IDL is cleared.
B) Thyroid hormone deficiency reduces cholesterol 7-alpha-hydroxylase (CYP7A1) activity, impairing bile acid synthesis and decreasing the primary route of hepatic cholesterol elimination; the resulting hepatocellular cholesterol excess downregulates LDLR expression through SREBP-2 suppression, reducing LDL clearance.
C) Thyroid hormone deficiency increases hepatic apolipoprotein B-100 synthesis by relieving thyroid hormone-mediated suppression of the apoB-100 gene, resulting in increased VLDL secretion and consequently increased downstream LDL production that accounts for the observed hypercholesterolemia.
D) Thyroid hormone deficiency suppresses scavenger receptor class B type I (SR-BI) on hepatocytes, impairing HDL-mediated reverse cholesterol transport and causing net cholesterol redistribution into LDL particles, raising measured LDL-C while simultaneously lowering HDL-C.
E) Thyroid hormone deficiency impairs LDL receptor (LDLR) expression on hepatocytes by reducing thyroid hormone-dependent transcriptional activity at regulatory elements in the LDLR gene promoter, decreasing receptor-mediated LDL clearance from the circulation and producing secondary hypercholesterolemia that typically resolves with thyroid hormone replacement therapy.
ANSWER: E
Rationale:
The correct answer is E. Thyroid hormones (primarily triiodothyronine, T3) directly stimulate hepatic LDLR expression through thyroid hormone response elements in the LDLR gene promoter. In hypothyroid states, reduced T3 signaling decreases LDLR transcription, reducing the number of functional receptors on hepatocyte surfaces. With fewer receptors available, receptor-mediated clearance of LDL from the circulation is impaired, and LDL-C rises. This is the dominant mechanism of hypothyroid hypercholesterolemia. Importantly, thyroid hormone replacement (levothyroxine) restores LDLR expression, and LDL-C typically normalizes or substantially improves within 6 to 12 weeks of achieving euthyroidism — making TSH measurement an essential first step before initiating or escalating lipid-lowering pharmacotherapy in any patient with unexplained hypercholesterolemia. Option B contains a partially correct observation — thyroid hormone does upregulate CYP7A1 and bile acid synthesis, and deficiency does reduce this pathway — but the primary mechanism driving LDL-C elevation is impaired LDLR expression (clearance), not reduced bile acid synthesis (production).
Option A: Option A is incorrect; while hepatic triglyceride lipase activity is reduced in hypothyroidism, impaired IDL-to-LDL conversion would actually reduce LDL production rather than raise LDL-C, and IDL does not meaningfully co-migrate with LDL in standard clinical assays to a degree that explains the observed LDL-C elevation.
Option C: Option C is incorrect; apoB-100 synthesis and VLDL secretion are not the principal mechanisms of hypothyroid hypercholesterolemia — increased VLDL output would primarily raise triglycerides and non-HDL-C, not selectively elevate LDL-C.
Option D: Option D is incorrect; SR-BI suppression affects reverse cholesterol transport and HDL metabolism, not LDL clearance directly; the described redistribution of cholesterol from HDL to LDL does not occur through this mechanism.
5. A 28-year-old man with known lipoprotein lipase (LPL) deficiency — confirmed by genetic testing showing homozygous loss-of-function mutations in the LPL gene — presents with fasting triglycerides of 2,800 mg/dL and a prior episode of acute pancreatitis. His physician explains that conventional lipid-lowering agents, including statins, fibrates, and niacin, have limited or no meaningful efficacy for his underlying condition. He is started on a very-low-fat diet and referred for evaluation for volanesorsen. Which of the following best explains why statins are ineffective for reducing triglycerides in LPL-deficient patients and why volanesorsen targets a different pathway?
A) Statins reduce hepatic VLDL secretion by inhibiting apoB-100 synthesis; in LPL-deficient patients, chylomicrons rather than VLDL are the dominant circulating triglyceride vehicle, and statin-mediated VLDL suppression cannot compensate for the absence of chylomicron clearance, leaving plasma triglycerides unchanged.
B) Statins act by inhibiting HMG-CoA reductase, reducing hepatic cholesterol synthesis and upregulating LDLR expression; they have no meaningful effect on triglyceride hydrolysis in peripheral tissues and do not compensate for absent LPL activity; volanesorsen is an antisense oligonucleotide (ASO) targeting apolipoprotein C-III (apoC-III) mRNA in the liver, reducing apoC-III — an endogenous LPL inhibitor — and thereby allowing residual or collateral triglyceride clearance mechanisms to function more effectively.
C) Statins reduce LDL-C through increased hepatic LDLR expression, which clears apoB-100-containing lipoproteins from the circulation; since chylomicrons carry apoB-48 rather than apoB-100, they are not cleared by LDLR even when receptor expression is maximally upregulated, and statin therapy cannot redirect chylomicron clearance; fibrates would be preferred over volanesorsen in this population.
D) Statins activate PPAR-α (peroxisome proliferator-activated receptor alpha) at high doses in a class-specific manner, upregulating LPL expression in peripheral tissues and reducing triglycerides through enhanced TG hydrolysis; this mechanism requires functional LPL enzyme as a downstream effector and is therefore completely inactive in patients with homozygous LPL deficiency.
E) Statins reduce triglycerides indirectly by lowering VLDL cholesterol, which reduces CETP-mediated triglyceride transfer from VLDL into LDL particles; in LPL-deficient patients, CETP activity is paradoxically increased and overwhelms the statin effect, making direct CETP inhibition with agents such as anacetrapib the treatment of choice.
ANSWER: B
Rationale:
The correct answer is B. Statins inhibit HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. Their primary pharmacological action reduces cholesterol, not triglycerides — they have no direct effect on LPL activity, triglyceride hydrolysis in peripheral capillaries, or chylomicron clearance. In LPL-deficient patients, dietary fat absorbed by the intestine is packaged into chylomicrons that accumulate massively in the circulation because the LPL enzyme required for their lipolysis in peripheral capillaries is absent. No statin, fibrate, or niacin can meaningfully substitute for the absent enzymatic activity. Volanesorsen is an antisense oligonucleotide (ASO) that binds to hepatic apoC-III mRNA, reducing its translation. ApoC-III (apolipoprotein C-III) is a potent endogenous inhibitor of LPL; it also inhibits hepatic uptake of triglyceride-rich lipoproteins by LDL receptor-related protein 1 (LRP1) through an LPL-independent mechanism. In patients with LPL deficiency, volanesorsen works through the LPL-independent hepatic uptake pathway, reducing plasma triglycerides even in the complete absence of functional LPL. This is why it represents a mechanistically rational therapy where conventional agents fail. Option C correctly identifies that chylomicrons carry apoB-48 rather than apoB-100 and are not cleared by LDLR, but incorrectly suggests fibrates are preferred over volanesorsen in LPL deficiency; fibrates upregulate LPL expression and activity through PPAR-α — a mechanism that requires functional LPL enzyme as an effector and is therefore ineffective in LPL-null patients.
Option A: Option A is incorrect; statins do not meaningfully suppress VLDL secretion or apoB-100 synthesis — VLDL suppression is not part of their mechanism of action.
Option D: Option D is incorrect; statins do not activate PPAR-α — that is the mechanism of the fibrate class (e.g., fenofibrate, gemfibrozil).
Option E: Option E is incorrect; CETP mediates lipid exchange between HDL and apoB-containing particles and does not directly hydrolyze triglycerides; CETP inhibition (anacetrapib, evacetrapib) is not indicated or studied in LPL deficiency.
6. A 66-year-old man with established atherosclerotic cardiovascular disease (ASCVD) — history of myocardial infarction two years prior — is on high-intensity atorvastatin plus ezetimibe. His most recent fasting lipid panel shows: LDL-C 58 mg/dL, HDL-C 38 mg/dL, triglycerides 310 mg/dL, total cholesterol 158 mg/dL. His physician calculates his non-HDL cholesterol and compares it to the appropriate treatment target for his risk category. Which of the following correctly identifies his non-HDL cholesterol value and the most appropriate non-HDL-C treatment target for this patient?
A) Non-HDL-C is 82 mg/dL; the appropriate non-HDL-C target for established ASCVD per the ACC/AHA framework is less than 80 mg/dL, which is 10 mg/dL above the corresponding LDL-C goal of less than 70 mg/dL and reflects the additional atherogenic contribution of VLDL cholesterol.
B) Non-HDL-C is 110 mg/dL; the appropriate non-HDL-C target for established ASCVD is less than 100 mg/dL, derived by adding 30 mg/dL to the LDL-C goal of less than 70 mg/dL, and this patient is above target primarily because of his elevated triglycerides raising VLDL cholesterol.
C) Non-HDL-C is 120 mg/dL; the appropriate non-HDL-C target for established ASCVD is less than 130 mg/dL, derived by adding 30 mg/dL to the LDL-C goal of less than 100 mg/dL for secondary prevention, and this patient is therefore at target.
D) Non-HDL-C is 120 mg/dL; the appropriate non-HDL-C target for established ASCVD is less than 100 mg/dL, derived by adding 30 mg/dL to the LDL-C goal of less than 70 mg/dL, and this patient is above target because his elevated triglycerides are raising VLDL cholesterol above the expected level.
E) Non-HDL-C is 58 mg/dL, identical to LDL-C in this patient because hypertriglyceridemia causes CETP-mediated transfer of cholesterol from VLDL into LDL, concentrating all atherogenic cholesterol in the LDL fraction; the non-HDL-C target for established ASCVD is less than 100 mg/dL and this patient is well below target.
ANSWER: D
Rationale:
The correct answer is D. Non-HDL cholesterol is calculated as total cholesterol minus HDL-C: 158 − 38 = 120 mg/dL. Non-HDL-C captures the cholesterol carried in all apolipoprotein B-containing atherogenic particles — including VLDL, IDL, LDL, and Lp(a) — and therefore accounts for the atherogenic burden of triglyceride-rich lipoprotein remnants that LDL-C alone misses, particularly relevant in patients with hypertriglyceridemia. The ACC/AHA framework specifies non-HDL-C targets as 30 mg/dL higher than the corresponding LDL-C target at each risk tier. For established ASCVD patients, the LDL-C target is less than 70 mg/dL; accordingly, the non-HDL-C target is less than 100 mg/dL. This patient's non-HDL-C of 120 mg/dL exceeds this target, driven by his elevated triglycerides — fasting TG of 310 mg/dL produces a VLDL-C of approximately 62 mg/dL (using the TG ÷ 5 estimate), which, added to his LDL-C of 58 mg/dL, accounts for much of the non-HDL-C elevation. Despite an LDL-C at target, this patient has residual non-HDL-C that warrants attention, illustrating why non-HDL-C is a more comprehensive treatment target in hypertriglyceridemic patients.
Option A: Option A is incorrect; non-HDL-C is 120 mg/dL, not 82 mg/dL, and the offset from the LDL-C goal is 30 mg/dL, not 10 mg/dL — the 10 mg/dL figure has no basis in the guideline framework.
Option B: Option B is incorrect on the non-HDL-C value; 158 − 38 = 120 mg/dL, not 110 mg/dL — the target of less than 100 mg/dL and the 30 mg/dL offset are correctly stated, but the calculated value is wrong.
Option C: Option C is incorrect on both the non-HDL-C target and the LDL-C goal it uses; the LDL-C target for established ASCVD (secondary prevention) is less than 70 mg/dL, not less than 100 mg/dL — the less than 100 mg/dL goal applies to lower-risk primary prevention populations.
Option E: Option E is incorrect; non-HDL-C is not equal to LDL-C — by definition it includes VLDL-C and IDL-C in addition to LDL-C, and the calculation (total cholesterol − HDL-C) clearly produces 120 mg/dL for this patient.
7. A 72-year-old man with a history of ischemic stroke 18 months ago, coronary artery disease with prior percutaneous coronary intervention (PCI), and peripheral arterial disease is evaluated in a preventive cardiology clinic. He is currently on high-intensity rosuvastatin 40 mg daily. His most recent LDL-C is 78 mg/dL. His physician classifies him as very high-risk secondary prevention based on the presence of multiple major ASCVD events. According to the 2018 ACC/AHA cholesterol guideline, which of the following most accurately describes the recommended next step in his lipid-lowering therapy?
A) He has not achieved his LDL-C target of less than 70 mg/dL for very high-risk secondary prevention; the guideline-endorsed next step is to add ezetimibe to his current high-intensity statin, and if the target is still not achieved on maximally tolerated statin plus ezetimibe, addition of a PCSK9 inhibitor is then recommended.
B) His LDL-C of 78 mg/dL is acceptable for standard secondary prevention; the ACC/AHA guideline reserves an LDL-C target of less than 70 mg/dL specifically for patients with familial hypercholesterolemia, and no additional therapy is indicated unless his LDL-C rises above 100 mg/dL on repeat testing.
C) His LDL-C of 78 mg/dL is above the very high-risk target, and the appropriate next step is to immediately add a PCSK9 inhibitor (evolocumab or alirocumab) as monotherapy, discontinuing rosuvastatin to simplify the regimen and improve adherence given his age and polypharmacy burden.
D) The ACC/AHA guideline does not specify an LDL-C numerical target for secondary prevention patients — it recommends high-intensity statin therapy by risk group; since he is already on high-intensity rosuvastatin, no further pharmacological escalation is guideline-endorsed regardless of LDL-C level.
E) His classification as very high-risk secondary prevention qualifies him for immediate PCSK9 inhibitor initiation as first-line add-on without requiring a prior trial of ezetimibe, because the guideline recognizes that the extreme atherogenic burden in multi-event patients justifies bypassing the stepwise approach.
ANSWER: A
Rationale:
The correct answer is A. The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol defines very high-risk secondary prevention as the presence of multiple major ASCVD events — which this patient satisfies (stroke, coronary artery disease with PCI, and peripheral arterial disease — three qualifying events) — or a single major event plus multiple high-risk conditions. For this group, the guideline endorses an LDL-C target of less than 70 mg/dL and recommends a stepwise escalation approach: first, confirm maximally tolerated high-intensity statin is in use; second, add ezetimibe if the less than 70 mg/dL target is not met; third, add a PCSK9 inhibitor if the target remains unmet on statin plus ezetimibe, given the cost-effectiveness data and the demonstrated event reduction in FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) and ODYSSEY OUTCOMES. This patient's LDL-C of 78 mg/dL is above the 70 mg/dL threshold, making ezetimibe addition the correct next step.
Option B: Option B is incorrect; the less than 70 mg/dL target is explicitly endorsed for very high-risk secondary prevention patients, not limited to familial hypercholesterolemia; a value of 78 mg/dL is above target and warrants action.
Option C: Option C is incorrect; the guideline does not recommend PCSK9 inhibitors as monotherapy replacing statins — statins remain the backbone of therapy, and PCSK9 inhibitors are add-on agents; discontinuing the statin would be inappropriate and contrary to guideline recommendations.
Option D: Option D is incorrect; while the ACC/AHA guideline is primarily intensity-based, it explicitly endorses the less than 70 mg/dL numerical target for very high-risk secondary prevention as a guide for add-on therapy decisions — numerical targets are not absent from the guideline.
Option E: Option E is incorrect; the 2018 ACC/AHA guideline does recommend a prior trial of ezetimibe before PCSK9 inhibitor initiation in most cases, citing cost-effectiveness; immediate PCSK9 inhibitor use without an ezetimibe trial is not the default guideline recommendation, although it may be appropriate in individual clinical circumstances.
8. A 54-year-old man with type 2 diabetes mellitus and abdominal obesity (BMI 33 kg/m²) presents for lipid management. His fasting results show: LDL-C 104 mg/dL, triglycerides 290 mg/dL, HDL-C 33 mg/dL, total cholesterol 175 mg/dL, HbA1c 8.1%. His physician explains that his LDL-C underestimates his true atherogenic particle burden and that his lipid profile is characteristic of a specific dyslipidemia phenotype driven by insulin resistance. Which of the following best describes the pathophysiological mechanism underlying his lipid phenotype and why his calculated LDL-C underestimates his atherogenic risk?
A) Insulin resistance reduces adipose tissue lipoprotein lipase (LPL) activity by impairing insulin-mediated LPL gene expression, producing a primary chylomicron clearance defect that raises postprandial triglycerides; hepatic uptake of excess chylomicron remnants then overwhelms LDLR capacity, raising LDL-C — but because remnant particles are counted separately from LDL in standard assays, this patient's calculated LDL-C substantially overestimates rather than underestimates his LDL particle number.
B) Insulin resistance activates hepatic sterol regulatory element-binding protein 1c (SREBP-1c) in a nutrient-sensing paradox: while insulin signaling for glucose metabolism is impaired, the lipogenic arm of insulin signaling remains intact, driving hepatic de novo triglyceride synthesis; this produces elevated VLDL secretion and high triglycerides, but LDL-C is raised rather than underestimated because VLDL-derived LDL particles are unusually cholesterol-rich in the insulin-resistant state.
C) Insulin resistance increases free fatty acid flux to the liver, driving hepatic de novo lipogenesis and increased VLDL secretion; elevated VLDL triggers CETP-mediated triglyceride-for-cholesterol exchange between VLDL and LDL, generating triglyceride-enriched LDL that is then remodeled by hepatic lipase into small, dense, cholesterol-depleted LDL particles; these particles carry less cholesterol per particle than normal LDL, so standard LDL-C measurement reflects cholesterol mass but not particle number, underestimating atherogenic burden — the classic diabetic dyslipidemia triad: elevated TG, low HDL-C, and predominance of small dense LDL.
D) Insulin resistance impairs hepatic PCSK9 degradation by reducing lysosomal acid lipase (LAL) activity, allowing PCSK9 to accumulate intracellularly rather than being secreted; paradoxically, intracellular PCSK9 accumulation activates an alternative LDLR degradation pathway that is more potent than the extracellular PCSK9 route, substantially reducing LDLR surface density and producing an LDL-C elevation that accurately reflects atherogenic particle number.
E) Insulin resistance impairs hepatic apoA-I synthesis through reduced PPAR-α activity, lowering HDL-C as a primary defect; reduced HDL-C allows greater LDL oxidation in the arterial wall, generating oxidized LDL particles that are internalized by macrophage scavenger receptors rather than hepatic LDLR, reducing measured plasma LDL-C while atherogenic particle deposition in the arterial intima continues — explaining why LDL-C underestimates atherogenic risk in this population.
ANSWER: C
Rationale:
The correct answer is C. The characteristic dyslipidemia of insulin resistance — often termed diabetic dyslipidemia or the atherogenic dyslipidemia triad — consists of elevated fasting and postprandial triglycerides, low HDL-C, and a predominance of small dense LDL (sdLDL) particles, despite LDL-C that may be normal or only modestly elevated. The mechanistic sequence is as follows: insulin resistance promotes adipose tissue lipolysis and hepatic free fatty acid uptake, driving de novo lipogenesis and increased hepatic VLDL-triglyceride secretion. Elevated plasma VLDL becomes the substrate for cholesteryl ester transfer protein (CETP)-mediated lipid exchange: CETP transfers triglycerides from VLDL into LDL and HDL in exchange for cholesterol esters, generating triglyceride-enriched LDL and HDL particles. Hepatic lipase (HL) then hydrolyzes the triglycerides from these particles, producing small, dense, cholesterol-depleted LDL. Because sdLDL particles carry substantially less cholesterol per particle than large buoyant LDL, a patient may have an elevated LDL particle number — and therefore high atherogenic risk — while their LDL-C (which reflects cholesterol mass, not particle number) appears normal or only modestly elevated. ApoB concentration, which reflects total atherogenic particle number regardless of particle size or cholesterol content, is the more accurate measure of atherogenic burden in this phenotype. Simultaneously, CETP-mediated cholesterol ester removal from HDL, combined with enhanced hepatic lipase-mediated HDL remodeling and accelerated apoA-I catabolism in the insulin-resistant state, produces low HDL-C.
Option A: Option A is incorrect; the mechanism described — adipose LPL impairment causing primary chylomicron clearance defect — is not the dominant pathophysiology of diabetic dyslipidemia, and the conclusion that LDL-C overestimates particle number is the opposite of what occurs with sdLDL predominance.
Option B: Option B is incorrect; while SREBP-1c activation is a real component of hepatic lipogenesis in insulin resistance, the claim that LDL particles are cholesterol-rich (rather than cholesterol-depleted) in this state is incorrect — sdLDL particles are defined by their relative cholesterol depletion.
Option D: Option D is incorrect; intracellular PCSK9 accumulation due to impaired LAL is not a recognized mechanism of insulin resistance dyslipidemia, and LAL deficiency is a separate rare lysosomal storage disorder.
Option E: Option E is incorrect; while reduced apoA-I synthesis contributes to low HDL-C in some insulin-resistant patients, the mechanism by which LDL-C underestimates atherogenic risk is sdLDL particle number — not selective intimal deposition of oxidized LDL reducing plasma LDL-C.
9. A clinical pharmacologist is reviewing the results of two major clinical trials of cholesteryl ester transfer protein (CETP) inhibitors — evacetrapib (ACCELERATE trial) and anacetrapib (REVEAL trial) — with a group of residents. Both agents substantially raised HDL-C (by 130% and 138%, respectively) yet neither produced the anticipated reduction in major cardiovascular events proportional to their HDL-C elevation. The pharmacologist explains that the failure of CETP inhibitors to reduce events at the magnitude predicted by HDL-C elevation reflects a fundamental limitation in how HDL-C is used as a pharmacological target. Which of the following best explains the mechanism of CETP and the conceptual basis for why raising HDL-C by CETP inhibition does not reliably translate into ASCVD event reduction?
A) CETP transfers triglycerides from HDL to LDL in exchange for cholesterol esters, lowering HDL-C and raising LDL-C under physiological conditions; CETP inhibitors reverse this exchange, raising HDL-C but also reducing LDL-C substantially, and the failure of CETP inhibitors is explained by off-target aldosterone-raising effects (torcetrapib) and insufficient LDL-C reduction in the other agents, rather than any limitation in HDL-C as a target.
B) CETP transfers cholesterol esters from HDL to apolipoprotein B-containing lipoproteins (VLDL and LDL) in exchange for triglycerides, returning cholesterol to the atherogenic lipoprotein pool; CETP inhibition raises HDL-C by blocking this exchange, but the resulting HDL particles are cholesterol-enriched and functionally impaired — they are less effective at promoting cholesterol efflux from macrophages via ABCA1 and SR-BI pathways, so the raised HDL-C reflects trapped cholesterol rather than enhanced reverse cholesterol transport capacity, providing no net atheroprotection.
C) CETP is only expressed in the arterial intima, where it catalyzes cholesterol transfer between subendothelial HDL and macrophage foam cells; CETP inhibitors block intimal cholesterol transfer rather than plasma lipid exchange, and their failure to reduce events reflects the inability of systemic HDL-C elevation to compensate for the pro-atherogenic intimal CETP activity that persists despite circulating CETP inhibition.
D) CETP transfers apolipoprotein A-I (apoA-I) between HDL subclasses, remodeling large HDL2 into smaller, more active HDL3 particles that are more efficient at initiating cholesterol efflux via ABCA1; CETP inhibition prevents this remodeling, raising HDL-C mass but accumulating large, dysfunctional HDL2 particles that have reduced ABCA1 interaction surface and impaired macrophage cholesterol efflux capacity.
E) CETP inhibition raises HDL-C by preventing hepatic SR-BI-mediated selective cholesterol ester uptake from HDL, causing cholesterol to remain trapped in circulating HDL particles rather than being delivered to the liver for biliary excretion; because hepatic SR-BI delivery is the terminal step of reverse cholesterol transport, CETP inhibition actually impairs rather than enhances net cholesterol removal from the body despite raising plasma HDL-C.
ANSWER: B
Rationale:
The correct answer is B. CETP (cholesteryl ester transfer protein) is a plasma glycoprotein that mediates bidirectional lipid exchange between HDL and apoB-containing lipoproteins (primarily VLDL and LDL): it transfers cholesterol esters from HDL to VLDL/LDL in exchange for triglycerides. This exchange redirects cholesterol esters from the HDL fraction — which would otherwise be delivered to the liver via scavenger receptor class B type I (SR-BI) — back into the atherogenic lipoprotein pool. CETP inhibition blocks this exchange, raising HDL-C by retaining cholesterol esters in HDL particles. The conceptual problem is that the resulting HDL particles — cholesterol-enriched and with reduced triglyceride content — are functionally different from the nascent, lipid-poor HDL particles that are most effective at accepting cholesterol from peripheral tissue macrophages via ABCA1 and SR-BI-mediated efflux. HDL-C as a plasma cholesterol concentration measures the cholesterol cargo of circulating HDL particles but does not reflect their functional capacity for cholesterol efflux. In CETP inhibitor trials, the massive HDL-C elevation reflected cholesterol accumulation in particles that had impaired ability to initiate new rounds of reverse cholesterol transport, not enhanced net cholesterol removal. This is the mechanistic basis for the trial failures and explains why HDL-C is a flawed pharmacological target: HDL function — not HDL-C concentration — determines atheroprotection. Option E partially describes the SR-BI pathway correctly but misattributes the mechanism of HDL-C elevation by CETP inhibition; CETP inhibition raises HDL-C by blocking cholesterol ester transfer to VLDL/LDL, not by blocking SR-BI-mediated hepatic uptake, and the two pathways are distinct.
Option A: Option A is incorrect in its description of CETP mechanism; CETP transfers cholesterol esters from HDL to VLDL/LDL (not triglycerides from HDL to LDL); while torcetrapib had aldosterone-raising off-target effects that confounded its trial (ILLUMINATE), the failures of evacetrapib (ACCELERATE) and anacetrapib (REVEAL) cannot be attributed to this mechanism — they reflect the fundamental HDL function limitation described above.
Option C: Option C is incorrect; CETP is a plasma protein circulating in the bloodstream, not restricted to the arterial intima — its lipid exchange activity occurs in the plasma compartment.
Option D: Option D is incorrect; CETP transfers lipids (cholesterol esters and triglycerides), not apolipoproteins — apoA-I transfer between HDL subclasses is not a CETP function.
10. A 61-year-old man with established ASCVD (prior myocardial infarction, coronary artery bypass surgery) has been on high-intensity rosuvastatin 40 mg daily for three years. His current LDL-C is 84 mg/dL, above his target of less than 70 mg/dL. His physician reviews guideline-recommended sequencing of combination lipid-lowering therapy and counsels the patient on the rationale for each step. Which of the following most accurately reflects the guideline-endorsed sequence for escalating lipid-lowering therapy in this patient, and the primary reason the sequence is structured in this order?
A) The recommended next step is to switch from rosuvastatin to a higher-potency statin such as pitavastatin, which upregulates LDLR expression through a distinct transcriptional pathway with less PCSK9 co-induction; ezetimibe and PCSK9 inhibitors are reserved for patients who fail two sequential statin switches.
B) The recommended next step is to add evolocumab or alirocumab immediately to his current high-intensity statin, because the ACC/AHA guideline endorses PCSK9 inhibitors as the preferred second-line agent for very high-risk secondary prevention patients based on superior cardiovascular event reduction data from FOURIER and ODYSSEY OUTCOMES compared to ezetimibe's IMPROVE-IT data.
C) The recommended sequence is to simultaneously add both ezetimibe and a PCSK9 inhibitor, because the ACC/AHA guideline for very high-risk secondary prevention endorses concurrent combination to minimize duration of above-target LDL-C exposure; sequential addition is reserved for lower-risk primary prevention patients.
D) The recommended sequence is: confirm maximally tolerated high-intensity statin first, then add ezetimibe if the LDL-C target is not achieved, then add a PCSK9 inhibitor if the target remains unmet on statin plus ezetimibe; this order reflects that ezetimibe is generic and inexpensive with proven cardiovascular event reduction from the IMPROVE-IT trial, making it the cost-effective step before escalating to PCSK9 inhibitor therapy.
E) The recommended sequence is statin followed by PCSK9 inhibitor followed by ezetimibe; ezetimibe is placed third rather than second because its intestinal mechanism does not complement the hepatic mechanism of PCSK9 inhibitors as effectively as it complements statins, and combining it with a PCSK9 inhibitor before optimizing that agent produces pharmacokinetic interference.
ANSWER: D
Rationale:
The correct answer is D. The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol endorses a stepwise escalation approach for patients not at their LDL-C target on high-intensity statin therapy. Step one is to confirm the patient is on the maximally tolerated high-intensity statin. Step two is to add ezetimibe if the LDL-C target is not achieved. Step three — applicable to very high-risk secondary prevention patients — is to add a PCSK9 inhibitor (evolocumab or alirocumab) if the target remains unmet on statin plus ezetimibe. The primary rationale for this ordering is cost-effectiveness: ezetimibe is widely available as an inexpensive generic, has a well-established safety profile, and produced a statistically significant 6.4% relative reduction in major cardiovascular events when added to statin therapy in the IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) trial. PCSK9 inhibitors, while highly effective and backed by robust event-reduction data from FOURIER and ODYSSEY OUTCOMES, remain substantially more expensive and are reserved for patients who do not achieve their target on statin plus ezetimibe. In clinical practice, the stepwise approach may be bypassed in patients with very high baseline LDL-C or recurrent ASCVD events where rapid and deep LDL-C reduction is a priority.
Option A: Option A is incorrect; pitavastatin does not have a distinct LDLR transcriptional pathway with less PCSK9 co-induction — all statins produce PCSK9 co-induction through SREBP-2 as a class effect, and switching statin agents is not a guideline-endorsed strategy for intensifying therapy when the patient is already on a high-intensity agent.
Option B: Option B is incorrect; while PCSK9 inhibitor event-reduction data are robust, the ACC/AHA guideline does not endorse PCSK9 inhibitors as the preferred second-line agent ahead of ezetimibe — cost-effectiveness considerations place ezetimibe first.
Option C: Option C is incorrect; simultaneous addition of both ezetimibe and a PCSK9 inhibitor is not the guideline default — the stepwise approach is endorsed for all risk categories, including very high-risk secondary prevention.
Option E: Option E is incorrect; the sequencing of ezetimibe before PCSK9 inhibitors is based on cost-effectiveness, not on any pharmacokinetic interaction or mechanistic incompatibility between ezetimibe and PCSK9 inhibitors — all three classes are mechanistically complementary and can be safely combined.
11. A 55-year-old man with heterozygous familial hypercholesterolemia (HeFH) and prior myocardial infarction at age 49 is on high-intensity atorvastatin plus ezetimibe plus evolocumab. His LDL-C is 48 mg/dL. Routine extended lipid panel reveals a lipoprotein(a) [Lp(a)] of 94 mg/dL. His cardiologist explains that his current regimen has a differential effect on Lp(a) compared to LDL-C, and that emerging targeted therapies are in development specifically for Lp(a) reduction. Which of the following most accurately describes the effect of his current medications on Lp(a) and the mechanism of the emerging Lp(a)-targeted agents?
A) PCSK9 inhibitors such as evolocumab reduce Lp(a) by approximately 20 to 25% through a mechanism that is incompletely understood but likely involves increased hepatic uptake of Lp(a) particles via upregulated LDLR surface density; statins modestly increase Lp(a) levels; and emerging targeted agents — including pelacarsen, an antisense oligonucleotide targeting apo(a) mRNA, and olpasiran, a small interfering RNA targeting hepatic apo(a) synthesis — reduce Lp(a) by 70 to 95% in clinical trials and represent a forthcoming class of highly potent Lp(a)-lowering therapies.
B) Statins reduce Lp(a) by approximately 20 to 30% through their SREBP-2-mediated upregulation of hepatic LDLR, which recognizes and clears Lp(a) particles via the apo(a) moiety; PCSK9 inhibitors have no meaningful effect on Lp(a) because Lp(a) particles are not cleared by LDLR-dependent pathways; and RNA-based agents target the apoB-100 component of Lp(a) rather than apo(a), reducing Lp(a) by suppressing its hepatic assembly.
C) Neither statins nor PCSK9 inhibitors have any meaningful effect on Lp(a) levels because Lp(a) is a genetically determined particle whose plasma concentration is regulated entirely at the level of hepatic secretion rather than receptor-mediated clearance, and all current lipid-lowering agents work exclusively through clearance pathways; RNA-based agents targeting apo(a) are the only intervention that can reduce Lp(a) by addressing its synthesis.
D) Ezetimibe reduces Lp(a) by approximately 15 to 20% through NPC1L1 inhibition; reduced intestinal cholesterol absorption decreases the hepatic substrate available for Lp(a) assembly, since Lp(a) is constructed in part from biliary cholesterol reabsorbed from the gut; statins and PCSK9 inhibitors have no clinically significant effect on Lp(a).
E) All three agents in this patient's regimen — statin, ezetimibe, and PCSK9 inhibitor — independently reduce Lp(a) by approximately 10 to 15% each, producing an additive total reduction of 30 to 45%; the emerging RNA-based agents are superior not because of a different mechanism but because they can be given to patients who are intolerant of all three conventional agents.
ANSWER: A
Rationale:
The correct answer is A. Lp(a) is a unique lipoprotein particle in which apolipoprotein(a) [apo(a)] is covalently linked to apoB-100 via a disulfide bond; its plasma concentration is more than 90% genetically determined by variation at the LPA gene locus and is largely unresponsive to lifestyle modification or conventional lipid-lowering therapy. PCSK9 inhibitors (evolocumab, alirocumab) reduce Lp(a) by approximately 20 to 25% — a clinically meaningful but partial reduction whose mechanism is incompletely elucidated; current evidence suggests that increased LDLR surface density may facilitate enhanced Lp(a) clearance, though alternative hepatic uptake pathways may also contribute. Statins, despite their potent LDL-C lowering, may paradoxically raise Lp(a) by modest amounts — the mechanism is uncertain but may involve statin-induced upregulation of apo(a) gene expression as part of the broader SREBP-2 transcriptional response. Ezetimibe has no clinically significant effect on Lp(a). The emerging targeted Lp(a)-lowering agents work at the level of hepatic apo(a) synthesis: pelacarsen is an antisense oligonucleotide (ASO) that hybridizes to apo(a) mRNA in hepatocytes, recruiting RNase H to degrade the transcript and reducing apo(a) protein production; olpasiran and zerlasiran are small interfering RNA (siRNA) agents that use the RNA-induced silencing complex (RISC) to cleave apo(a) mRNA. Both ASO and siRNA approaches achieve 70 to 95% Lp(a) reduction in phase II trials, far exceeding anything achievable with conventional lipid-lowering therapy, and are in late-phase cardiovascular outcomes trials.
Option B: Option B is incorrect on multiple counts: statins do not reduce Lp(a) — they may raise it modestly; PCSK9 inhibitors do have a meaningful 20 to 25% Lp(a)-reducing effect; and RNA agents target apo(a), not apoB-100.
Option C: Option C is incorrect in stating that no current agent has any meaningful effect on Lp(a) — PCSK9 inhibitors produce a reproducible 20 to 25% reduction — and in claiming all lipid-lowering agents work exclusively through clearance pathways; statins work through synthesis inhibition.
Option D: Option D is incorrect; ezetimibe has no established clinically significant effect on Lp(a), and the proposed mechanism is not supported by evidence.
Option E: Option E is incorrect; ezetimibe does not reduce Lp(a), and the three-agent additive reduction described is not consistent with established data.
12. A 34-year-old woman with no prior cardiovascular events, no diabetes, and no significant family history presents for a routine physical. Her fasting lipid panel reveals: LDL-C 214 mg/dL, HDL-C 58 mg/dL, triglycerides 88 mg/dL, total cholesterol 290 mg/dL. She is a non-smoker, normotensive, and her calculated 10-year ASCVD risk using the Pooled Cohort Equations (PCE) is 1.8% (low risk). A medical student observing the visit asks why the physician is recommending high-intensity statin therapy given her very low calculated 10-year risk. Which of the following best explains the guideline rationale for initiating high-intensity statin therapy in this patient without relying on her 10-year risk calculation?
A) The 2018 ACC/AHA guideline recommends high-intensity statin therapy for all women under age 40 with LDL-C above 130 mg/dL because the Pooled Cohort Equations systematically underestimate 10-year ASCVD risk in young women; the PCE are validated only for patients between ages 40 and 79 and produce unreliable risk estimates below this age range, making the numerical output clinically meaningless in this patient.
B) Patients with LDL-C above 190 mg/dL who are under age 40 are automatically classified as having familial hypercholesterolemia (FH) and are therefore referred directly to a lipid specialist for cascade genetic testing; statin therapy is initiated only after genetic confirmation of an LDL receptor mutation, as empirical statin prescribing without a confirmed FH diagnosis is not guideline-endorsed.
C) The 2018 ACC/AHA guideline endorses high-intensity statin therapy for patients with fasting triglycerides below 100 mg/dL and LDL-C above 190 mg/dL because the combination of high LDL-C and low triglycerides is the biochemical signature of familial hypercholesterolemia; triglyceride level, not LDL-C alone, is the key discriminating variable that triggers the guideline recommendation in this risk group.
D) The 10-year risk calculation is appropriate for primary prevention decisions in patients aged 40 to 75; for patients outside this age range, the ACC/AHA guideline recommends using the Framingham Lifetime Risk Calculator instead, and this patient's lifetime risk — estimated at approximately 40% — triggers the high-intensity statin recommendation independent of her 10-year PCE estimate.
E) The 2018 ACC/AHA guideline identifies patients with LDL-C of 190 mg/dL or greater as a distinct benefit group warranting high-intensity statin therapy without requiring 10-year risk calculation, because their lifetime cumulative exposure to elevated LDL-C confers a disproportionate atherogenic burden that exceeds what any short-term risk model captures; this category encompasses most cases of heterozygous familial hypercholesterolemia and warrants treatment based on LDL-C level alone.
ANSWER: E
Rationale:
The correct answer is E. The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol identifies four benefit groups for whom statin therapy has demonstrated net clinical benefit. Group 2 — patients with primary LDL-C of 190 mg/dL or greater — is unique in that guideline recommendations for this group do not require formal 10-year ASCVD risk calculation. The rationale is that patients with markedly elevated LDL-C from early life accumulate atherogenic burden cumulatively over decades, producing a lifetime cardiovascular risk that is substantially higher than any 10-year risk model can capture, particularly in young patients in whom most of the risk lies beyond the 10-year horizon. The Pooled Cohort Equations are validated for patients aged 40 to 79 and produce short-term risk estimates that inevitably appear low in young patients regardless of their LDL burden; applying this tool as a gating criterion for treatment in this population would systematically withhold therapy from those who stand to gain the most lifetime benefit. An LDL-C of 190 mg/dL or greater also captures most cases of heterozygous familial hypercholesterolemia, though FH can be present at lower LDL-C values and genetic testing is not required before initiating therapy. The guideline recommendation is high-intensity statin as the starting point, with a goal of at least 50% LDL-C reduction.
Option A: Option A is incorrect; while the PCE are indeed validated for patients aged 40 to 79, the guideline's reason for not requiring risk calculation in this patient is her LDL-C level (Group 2 criterion) — not her age. The guideline does not recommend high-intensity statin for all women under 40 with LDL-C above 130 mg/dL.
Option B: Option B is incorrect; the guideline does not require genetic confirmation of an LDL receptor mutation before initiating statin therapy; empirical high-intensity statin therapy based on LDL-C level alone is guideline-endorsed, and genetic testing may be useful for cascade family screening but is not a prerequisite for treatment.
Option C: Option C is incorrect; the Group 2 criterion is LDL-C of 190 mg/dL or greater, with no requirement for a specific triglyceride level; triglyceride concentration is not the discriminating variable in this guideline category.
Option D: Option D is incorrect; the ACC/AHA guideline does not recommend using the Framingham Lifetime Risk Calculator as a substitute for the PCE in patients outside the 40 to 79 age range — the Group 2 recommendation bypasses risk calculation entirely based on the LDL-C threshold alone.
13. A biochemist is lecturing on the final step of reverse cholesterol transport (RCT) — the delivery of peripheral tissue cholesterol to the liver for biliary excretion. She explains that this terminal hepatic uptake step involves a receptor that is mechanistically and structurally distinct from the LDL receptor and that is not upregulated by statins or inhibited by PCSK9. A resident asks which receptor mediates this step and how it differs functionally from the LDLR in its mode of cholesterol uptake. Which of the following correctly identifies the hepatic receptor responsible for the terminal step of RCT and accurately describes its mechanism?
A) The LDL receptor-related protein 1 (LRP1) mediates terminal RCT by binding the apoE moiety on mature HDL particles, internalizing the entire HDL particle via clathrin-mediated endocytosis, and delivering its cholesterol ester cargo to lysosomes for hydrolysis and subsequent biliary excretion — the same whole-particle uptake mechanism used by LDLR for LDL clearance.
B) The ATP-binding cassette transporter A1 (ABCA1) mediates terminal hepatic cholesterol uptake from HDL by facilitating cholesterol efflux in reverse — running the ABCA1 transporter in its hepatic uptake direction rather than its peripheral tissue efflux direction — and delivering free cholesterol directly into bile canaliculi without lysosomal processing.
C) Scavenger receptor class B type I (SR-BI) mediates the terminal step of RCT by selectively transferring cholesterol esters from circulating HDL particles into hepatocytes without internalizing the entire HDL particle; the lipid-depleted HDL is then released back into the circulation to accept additional cholesterol from peripheral tissues, making SR-BI functionally distinct from LDLR, which internalizes the entire LDL particle via clathrin-mediated endocytosis.
D) The hepatic ABCG5/G8 heterodimer mediates terminal RCT by transporting cholesterol esters from the hepatocyte cytoplasm into bile canaliculi; it receives cholesterol directly from circulating HDL via a docking interaction at the canalicular membrane, transferring cholesterol without particle internalization in a process driven by the bile salt concentration gradient.
E) Cubilin, a multiligand endocytic receptor expressed on hepatocytes, mediates terminal RCT by binding apoA-I on mature HDL2 particles and internalizing the entire HDL particle via megalin-dependent endocytosis; the internalized cholesterol esters are hydrolyzed in lysosomes and secreted into bile as free cholesterol, while apoA-I is recycled to the plasma membrane and re-secreted as pre-beta HDL.
ANSWER: C
Rationale:
The correct answer is C. Scavenger receptor class B type I (SR-BI) is the primary hepatic receptor responsible for the terminal step of reverse cholesterol transport. SR-BI mediates selective lipid uptake — a mechanism fundamentally distinct from the receptor-mediated endocytosis used by the LDL receptor. In selective uptake, SR-BI on the hepatocyte surface docks with circulating mature HDL particles and facilitates the transfer of cholesterol esters from the HDL core directly into the hepatocyte, without internalizing the HDL particle itself. The lipid-depleted, now relatively protein-rich HDL particle is released intact back into the circulation, where it can resume cholesterol efflux activity from peripheral tissues — effectively recharging the HDL particle for additional rounds of reverse cholesterol transport. This mechanism is the critical terminus of the RCT pathway: cholesterol acquired from peripheral tissue macrophages, esterified by lecithin:cholesterol acyltransferase (LCAT) during HDL maturation, and enriched in the HDL core is ultimately delivered to the liver via SR-BI for conversion to bile acids by CYP7A1 or direct secretion into bile. SR-BI expression is regulated by hepatic cholesterol status and is distinct from LDLR regulation — it is neither upregulated by statin-mediated SREBP-2 activation nor subject to PCSK9-mediated degradation, making it a pharmacologically independent clearance pathway.
Option A: Option A is incorrect; LRP1 mediates hepatic clearance of chylomicron remnants and VLDL remnants (using apoE as the ligand) — it is not the primary receptor for HDL-mediated terminal RCT, and mature HDL does not carry the apoE content required for high-affinity LRP1 binding.
Option B: Option B is incorrect; ABCA1 is a cholesterol efflux transporter expressed in peripheral tissue macrophages and other cells — it mediates the first step of RCT (cholesterol efflux from macrophages to nascent HDL), not the terminal hepatic uptake step; ABCA1 does not run in reverse as a hepatic uptake mechanism.
Option D: Option D is incorrect; ABCG5/G8 is a canalicular transporter that secretes plant sterols and cholesterol into bile from within the hepatocyte, but it does not directly receive cholesterol from circulating HDL at the sinusoidal membrane — it is a downstream secretory step within the hepatocyte, not the initial docking receptor for HDL.
Option E: Option E is incorrect; while cubilin and megalin-mediated endocytosis of apoA-I has been described in the kidney as a pathway for HDL catabolism, this is not the primary mechanism of hepatic terminal RCT — SR-BI is the established principal hepatic HDL cholesterol uptake receptor.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.